<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31002702</PMID><DateCompleted><Year>2020</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>4</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants.</ArticleTitle><Pagination><StartPage>e0215079</StartPage><MedlinePgn>e0215079</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0215079</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0215079</ELocationID><Abstract><AbstractText Label="INTRODUCTION">The prevalence of HIV infection in South African pregnant women has been approximately 30% over the past decade; however, there has been a steady decline in mother-to-child transmission of HIV from 8% in 2008 to &lt;2% in 2015. We evaluated the immunogenicity of live-attenuated trivalent oral polio vaccine (OPV) following the primary vaccination series (doses at birth, 6, 10 and 14 weeks of age) in HIV-exposed uninfected (HEU), HIV-infected infants initiated on early anti-retroviral treatment (HIV+/ART+), HIV-infected infants on deferred ART (HIV+/ART-) and HIV-unexposed infants (HU) as the referent group.</AbstractText><AbstractText Label="METHODS">Serum polio neutralization antibody titres were evaluated to serotype-1, serotype-2 and serotype-3 at 6, 10 and 18 weeks of age. Antibody titres &#x2265;8 were considered seropositive and sero-protective.</AbstractText><AbstractText Label="RESULTS">At 18 weeks of age, following the complete primary series of four OPV doses, no differences in GMTs, percentage of infants with sero-protective titres and median fold change in antibody titre (18 weeks vs 6 weeks) were observed in HEU infants (n = 114) and HIV+/ART+ infants (n = 162) compared to HU infants (n = 104) for the three polio serotypes. However, comparing HIV+/ART- infants (n = 70) to HU infants at 18 weeks of age, we observed significantly lower GMTs for serotype-1 (p = 0.022), serotype-2 (p&lt;0.001) and serotype-3 (p&lt;0.001), significantly lower percentages of infants with sero-protective titres for the three serotypes (p&lt;0.001), and significantly lower median fold change in antibody titre for serotype-1 (p = 0.048), serotype-2 (p = 0.003) and serotype-3 (p = 0.008).</AbstractText><AbstractText Label="CONCLUSION">Delaying initiation of ART in HIV-infected infants was associated with an attenuated immune response to OPV following a four-dose primary series of vaccines, whereas immune responses to OPV in HIV-infected children initiated on ART early in infancy and HEU children were similar to HU infants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moonsamy</LastName><ForeName>Shelina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8490-8977</Identifier><AffiliationInfo><Affiliation>Centre for Vaccines and Immunology, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Sciences, University of Johannesburg, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Melinda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Vaccines and Immunology, National Institute for Communicable Diseases, a division of the National Health Laboratory Service, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemical Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhi</LastName><ForeName>Shabir A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>South African Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Science and Technology, National Research Foundation, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044966">Anti-Retroviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D023321">Poliovirus Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D044966" MajorTopicYN="N">Anti-Retroviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000635" MajorTopicYN="Y">transmission</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018445" MajorTopicYN="N">Infectious Disease Transmission, Vertical</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023321" MajorTopicYN="N">Poliovirus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31002702</ArticleId><ArticleId IdType="pmc">PMC6474646</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0215079</ArticleId><ArticleId IdType="pii">PONE-D-18-33227</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anya BM, Moturi E, Aschalew T, Carole Tevi-Benissan M, Akanmori BD, Poy AN, et al. Contribution of polio eradication initiative to strengthening routine immunization: Lessons learnt in the WHO African region. Vaccine. 2016;34(43):5187&#x2013;92. 10.1016/j.vaccine.2016.05.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.05.062</ArticleId><ArticleId IdType="pubmed">27396492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10(5):791&#x2013;808. 10.2217/fmb.15.19</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fmb.15.19</ArticleId><ArticleId IdType="pubmed">25824845</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasir UN, Bandyopadhyay AS, Montagnani F, Akite JE, Mungu EB, Uche IV, et al. Polio elimination in Nigeria: A review. Hum Vaccin Immunother. 2016;12(3):658&#x2013;63. 10.1080/21645515.2015.1088617</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1088617</ArticleId><ArticleId IdType="pmc">PMC4964709</ArticleId><ArticleId IdType="pubmed">26383769</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman GG, Mazanderani AH, Barron P, Bhardwaj S, Niit R, Okobi M, et al. Toward elimination of mother-to-child transmission of HIV in South Africa: how best to monitor early infant infections within the Prevention of Mother-to-Child Transmission Program. J Glob Health. 2017;7(1):010701 10.7189/jogh.07.010701</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.07.010701</ArticleId><ArticleId IdType="pmc">PMC5441442</ArticleId><ArticleId IdType="pubmed">28567281</ArticleId></ArticleIdList></Reference><Reference><Citation>South African Medical Research Council. Early mother-to-child transmission of HIV stats plunge 2016 [http://www.mrc.ac.za/media-release/early-mother-child-transmission-hiv-stats-plunge.</Citation></Reference><Reference><Citation>Bhardwaj S, Barron P, Pillay Y, Treger-Slavin L, Robinson P, Goga A, et al. Elimination of mother-to-child transmission of HIV in South Africa: rapid scale-up using quality improvement. S Afr Med J. 2014;104(3 Suppl 1):239&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">24893500</ArticleId></ArticleIdList></Reference><Reference><Citation>Afran L, Garcia Knight M, Nduati E, Urban BC, Heyderman RS, Rowland-Jones SL. HIV-exposed uninfected children: a growing population with a vulnerable immune system? Clin Exp Immunol. 2014;176(1):11&#x2013;22. 10.1111/cei.12251</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.12251</ArticleId><ArticleId IdType="pmc">PMC3958150</ArticleId><ArticleId IdType="pubmed">24325737</ArticleId></ArticleIdList></Reference><Reference><Citation>Goetghebuer T, Rowland-Jones SL, Kollmann TR. Editorial: Immune Mechanisms Underlying the Increased Morbidity and Mortality of HIV-Exposed Uninfected (HEU) Children. Front Immunol. 2017;8:1060 10.3389/fimmu.2017.01060</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01060</ArticleId><ArticleId IdType="pmc">PMC5593069</ArticleId><ArticleId IdType="pubmed">28932223</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raya B, Kollmann TR, Marchant A, MacGillivray DM. The Immune System of HIV-Exposed Uninfected Infants. Front Immunol. 2016;7:383 10.3389/fimmu.2016.00383</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00383</ArticleId><ArticleId IdType="pmc">PMC5039172</ArticleId><ArticleId IdType="pubmed">27733852</ArticleId></ArticleIdList></Reference><Reference><Citation>Morden E, Technau KG, Giddy J, Maxwell N, Keiser O, Davies MA. Growth of HIV-Exposed Uninfected Infants in the First 6 Months of Life in South Africa: The IeDEA-SA Collaboration. PLoS One. 2016;11(4):e0151762 10.1371/journal.pone.0151762</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0151762</ArticleId><ArticleId IdType="pmc">PMC4822941</ArticleId><ArticleId IdType="pubmed">27049853</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerneis S, Launay O, Turbelin C, Batteux F, Hanslik T, Boelle PY. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(8):1130&#x2013;9. 10.1093/cid/cit937</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit937</ArticleId><ArticleId IdType="pmc">PMC4761378</ArticleId><ArticleId IdType="pubmed">24415637</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy SB, Kouiavskaia D, Siik J, Kochba E, Beydoun H, Mirochnitchenko O, et al. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. J Infect Dis. 2015;211(12):1969&#x2013;76. 10.1093/infdis/jiu841</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu841</ArticleId><ArticleId IdType="pmc">PMC4539908</ArticleId><ArticleId IdType="pubmed">25567841</ArticleId></ArticleIdList></Reference><Reference><Citation>Simani OE, Adrian PV, Violari A, Kuwanda L, Otwombe K, Nunes MC, et al. Effect of in-utero HIV exposure and antiretroviral treatment strategies on measles susceptibility and immunogenicity of measles vaccine. AIDS. 2013;27(10):1583&#x2013;91. 10.1097/QAD.0b013e32835fae26</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0b013e32835fae26</ArticleId><ArticleId IdType="pubmed">24047763</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejiokem MC, Gouandjika I, Beniguel L, Zanga MC, Tene G, Gody JC, et al. HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the Expanded Program on Immunization. PLoS One. 2007;2(12):e1260 10.1371/journal.pone.0001260</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0001260</ArticleId><ArticleId IdType="pmc">PMC2093997</ArticleId><ArticleId IdType="pubmed">18060056</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol. 2006;4(12):900&#x2013;8. 10.1038/nrmicro1550</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro1550</ArticleId><ArticleId IdType="pmc">PMC7097605</ArticleId><ArticleId IdType="pubmed">17088933</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott P, Moss WJ, Gilani Z, Low N. Measles vaccination in HIV-infected children: systematic review and meta-analysis of safety and immunogenicity. J Infect Dis. 2011;204 Suppl 1:S164&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">21666158</ArticleId></ArticleIdList></Reference><Reference><Citation>Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233&#x2013;44. 10.1056/NEJMoa0800971</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0800971</ArticleId><ArticleId IdType="pmc">PMC2950021</ArticleId><ArticleId IdType="pubmed">19020325</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins IJ, Jourdain G, Hansudewechakul R, Kanjanavanit S, Hongsiriwon S, Ngampiyasakul C, et al. Long-term survival of HIV-infected children receiving antiretroviral therapy in Thailand: a 5-year observational cohort study. Clin Infect Dis. 2010;51(12):1449&#x2013;57. 10.1086/657401</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/657401</ArticleId><ArticleId IdType="pmc">PMC3106246</ArticleId><ArticleId IdType="pubmed">21054181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Barradas MC, Musher DM, Lahart C, Lacke C, Groover J, Watson D, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis. 1992;165(3):553&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1347058</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi SA, Adrian P, Cotton MF, McIntyre JA, Jean-Philippe P, Meadows S, et al. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. J Infect Dis. 2010;202(3):355&#x2013;61. 10.1086/653704</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/653704</ArticleId><ArticleId IdType="pmc">PMC2902789</ArticleId><ArticleId IdType="pubmed">20583920</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS. 2009;20(9):595&#x2013;600. 10.1258/ijsa.2009.009126</Citation><ArticleIdList><ArticleId IdType="doi">10.1258/ijsa.2009.009126</ArticleId><ArticleId IdType="pubmed">19710329</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagigi A, Cotugno N, Giaquinto C, Nicolosi L, Bernardi S, Rossi P, et al. Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions. Hum Vaccin Immunother. 2012;8(12):1784&#x2013;94. 10.4161/hv.21827</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21827</ArticleId><ArticleId IdType="pmc">PMC3656066</ArticleId><ArticleId IdType="pubmed">22906931</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryder RW, Oxtoby MJ, Mvula M, Batter V, Baende E, Nsa W, et al. Safety and immunogenicity of bacille Calmette-Guerin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr. 1993;122(5 Pt 1):697&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">8496745</ArticleId></ArticleIdList></Reference><Reference><Citation>Falco V, Jordano Q, Cruz MJ, Len O, Ribera E, Campins M, et al. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study. Vaccine. 2006;24(14):2567&#x2013;74. 10.1016/j.vaccine.2005.12.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.021</ArticleId><ArticleId IdType="pubmed">16423429</ArticleId></ArticleIdList></Reference><Reference><Citation>Church JA, Rukobo S, Govha M, Carmolli MP, Diehl SA, Chasekwa B, et al. Immune responses to oral poliovirus vaccine in HIV-exposed uninfected Zimbabwean infants. Hum Vaccin Immunother. 2017;13(11):2543&#x2013;7. 10.1080/21645515.2017.1359454</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2017.1359454</ArticleId><ArticleId IdType="pmc">PMC5703368</ArticleId><ArticleId IdType="pubmed">28857649</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz-Ramos M, Manno D, Kapambwe M, Ndumba I, Musonda KG, Bates M, et al. Reduced Poliovirus vaccine neutralising-antibody titres in infants with maternal HIV-exposure. Vaccine. 2013;31(16):2042&#x2013;9. 10.1016/j.vaccine.2013.02.044</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.02.044</ArticleId><ArticleId IdType="pubmed">23474309</ArticleId></ArticleIdList></Reference><Reference><Citation>Troy SB, Musingwini G, Halpern MS, Huang C, Stranix-Chibanda L, Kouiavskaia D, et al. Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants. J Infect Dis. 2013;208(4):672&#x2013;8. 10.1093/infdis/jit208</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jit208</ArticleId><ArticleId IdType="pmc">PMC3719901</ArticleId><ArticleId IdType="pubmed">23661792</ArticleId></ArticleIdList></Reference><Reference><Citation>Expanded Programme on Immunisation. New EPI Vaccines Guidelines: The National Department of Health, Republic of South Africa, 2009 [updated October 2010. https://www.health-e.org.za/wp-content/uploads/2014/02/South-Africa-EPI-vaccines-revised-Oct-2010.pdf.</Citation></Reference><Reference><Citation>Feoktistova M, Geserick P, Leverkus M. Crystal Violet Assay for Determining Viability of Cultured Cells. Cold Spring Harb Protoc. 2016;2016(4):pdb prot087379.</Citation><ArticleIdList><ArticleId IdType="pubmed">27037069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol. 2016;5(2):85&#x2013;6. 10.5501/wjv.v5.i2.85</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v5.i2.85</ArticleId><ArticleId IdType="pmc">PMC4861875</ArticleId><ArticleId IdType="pubmed">27175354</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Salort M, Molodecky NA, O&#x2019;Reilly KM, Wadood MZ, Safdar RM, Etsano A, et al. Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data. PLoS Med. 2016;13(10):e1002140 10.1371/journal.pmed.1002140</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002140</ArticleId><ArticleId IdType="pmc">PMC5049753</ArticleId><ArticleId IdType="pubmed">27701425</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin Microbiol Infect. 2005;11(1):68&#x2013;71. 10.1111/j.1469-0691.2004.00998.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2004.00998.x</ArticleId><ArticleId IdType="pubmed">15649308</ArticleId></ArticleIdList></Reference><Reference><Citation>Drexler JF, Grard G, Lukashev AN, Kozlovskaya LI, Bottcher S, Uslu G, et al. Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc Natl Acad Sci U S A. 2014;111(35):12889&#x2013;94. 10.1073/pnas.1323502111</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1323502111</ArticleId><ArticleId IdType="pmc">PMC4156724</ArticleId><ArticleId IdType="pubmed">25136105</ArticleId></ArticleIdList></Reference><Reference><Citation>Asturias EJ, Dueger EL, Omer SB, Melville A, Nates SV, Laassri M, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis. 2007;196(5):692&#x2013;8. 10.1086/520546</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/520546</ArticleId><ArticleId IdType="pubmed">17674310</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine PE. Polio: measuring the protection that matters most. J Infect Dis. 2009;200(5):673&#x2013;5. 10.1086/605331</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/605331</ArticleId><ArticleId IdType="pubmed">19624277</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M, Iwai M, Wakita T, Shimizu H. Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum. Clin Vaccine Immunol. 2011;18(11):1889&#x2013;94. 10.1128/CVI.05225-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.05225-11</ArticleId><ArticleId IdType="pmc">PMC3209023</ArticleId><ArticleId IdType="pubmed">21880850</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401&#x2013;9. 10.1086/589862</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/589862</ArticleId><ArticleId IdType="pubmed">18558875</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel M, Cochi S. Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future. J Infect Dis. 2017;216(suppl_1):S1&#x2013;S8. 10.1093/infdis/jix117</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jix117</ArticleId><ArticleId IdType="pmc">PMC5853839</ArticleId><ArticleId IdType="pubmed">28838196</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez Gonzalez A, Farrell M, Menning L, Garon J, Everts H, Hampton LM, et al. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective. J Infect Dis. 2017;216(suppl_1):S183&#x2013;S92. 10.1093/infdis/jiw626</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiw626</ArticleId><ArticleId IdType="pmc">PMC5854099</ArticleId><ArticleId IdType="pubmed">28838179</ArticleId></ArticleIdList></Reference><Reference><Citation>Palma P, Romiti ML, Cancrini C, Pensieroso S, Montesano C, Bernardi S, et al. Delayed early antiretroviral treatment is associated with an HIV-specific long-term cellular response in HIV-1 vertically infected infants. Vaccine. 2008;26(40):5196&#x2013;201. 10.1016/j.vaccine.2008.03.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.03.062</ArticleId><ArticleId IdType="pubmed">18471944</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensieroso S, Cagigi A, Palma P, Nilsson A, Capponi C, Freda E, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci U S A. 2009;106(19):7939&#x2013;44. 10.1073/pnas.0901702106</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0901702106</ArticleId><ArticleId IdType="pmc">PMC2683072</ArticleId><ArticleId IdType="pubmed">19416836</ArticleId></ArticleIdList></Reference><Reference><Citation>Romiti ML, Cancrini C, Castelli-Gattinara G, Di Cesare S, Ciaffi P, Bernardi S, et al. Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART. AIDS. 2001;15(16):2075&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">11684926</ArticleId></ArticleIdList></Reference><Reference><Citation>de Moraes-Pinto MI, Almeida AC, Kenj G, Filgueiras TE, Tobias W, Santos AM, et al. Placental transfer and maternally acquired neonatal IgG immunity in human immunodeficiency virus infection. J Infect Dis. 1996;173(5):1077&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">8627057</ArticleId></ArticleIdList></Reference><Reference><Citation>de Moraes-Pinto MI, Verhoeff F, Chimsuku L, Milligan PJ, Wesumperuma L, Broadhead RL, et al. Placental antibody transfer: influence of maternal HIV infection and placental malaria. Arch Dis Child Fetal Neonatal Ed. 1998;79(3):F202&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1720856</ArticleId><ArticleId IdType="pubmed">10194992</ArticleId></ArticleIdList></Reference><Reference><Citation>Borba RC, Vidal VM, Moreira LO. The re-emergency and persistence of vaccine preventable diseases. An Acad Bras Cienc. 2015;87(2 Suppl):1311&#x2013;22. 10.1590/0001-3765201520140663</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0001-3765201520140663</ArticleId><ArticleId IdType="pubmed">26312431</ArticleId></ArticleIdList></Reference><Reference><Citation>Doherty M, Buchy P, Standaert B, Giaquinto C, Prado-Cohrs D. Vaccine impact: Benefits for human health. Vaccine. 2016;34(52):6707&#x2013;14. 10.1016/j.vaccine.2016.10.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.10.025</ArticleId><ArticleId IdType="pubmed">27773475</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern PL. The changing face of vaccines and vaccination. Vaccine. 2016;34(52):6653&#x2013;4. 10.1016/j.vaccine.2016.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2016.11.014</ArticleId><ArticleId IdType="pubmed">27866771</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov AP, Dragunsky EM. ELISA as a possible alternative to the neutralization test for evaluating the immune response to poliovirus vaccines. Expert Rev Vaccines. 2005;4(2):167&#x2013;72. 10.1586/14760584.4.2.167</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.4.2.167</ArticleId><ArticleId IdType="pubmed">15889990</ArticleId></ArticleIdList></Reference><Reference><Citation>Simhon A, Lifshitz A, Abed Y, Lasch EE, Schoub B, Morag A. How to predict the immune status of poliovirus vaccinees? A comparison of virus neutralization at a very low serum dilution versus ELISA in a cohort of infants. Int J Epidemiol. 1990;19(1):164&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2161806</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoub BD. Introduction of inactivated polio vaccine (IPV) into the routine immunization schedule of South Africa. Vaccine. 2012;30 Suppl 3:C35&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22939019</ArticleId></ArticleIdList></Reference><Reference><Citation>Canals F, Masia M, Gutierrez F. Developments in early diagnosis and therapy of HIV infection in newborns. Expert Opin Pharmacother. 2018;19(1):13&#x2013;25. 10.1080/14656566.2017.1363180</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1363180</ArticleId><ArticleId IdType="pubmed">28764578</ArticleId></ArticleIdList></Reference><Reference><Citation>Sturt A, Troy SB. Overcoming the barriers to timely antiretroviral initiation in HIV-infected infants. J Trop Pediatr. 2014;60(4):267&#x2013;9. 10.1093/tropej/fmu044</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/tropej/fmu044</ArticleId><ArticleId IdType="pubmed">25085461</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>